Oncuria

About Nonagen Bioscience

Nonagen Bioscience is a private, pre-revenue diagnostics company founded in 2011 and headquartered in San Diego, California. The company is developing a multiplex protein immunoassay platform, with its lead candidate, Oncuria®, targeting bladder cancer for detection, recurrence monitoring, and therapy response prediction. As a physician-led organization, Nonagen's mission is to reduce the global burden of cancer by providing innovative diagnostic tools to improve clinical decision-making and patient outcomes.

About DiaCarta

DiaCarta is a commercial-stage diagnostics company with a focus on oncology and infectious diseases, utilizing its proprietary XNA and isobDNA™ technologies to enhance mutation detection sensitivity. Its product portfolio includes liquid biopsy tests for cancer therapy monitoring (RadTox™), colorectal cancer screening (ColoScape™), and bladder cancer detection (Oncuria®), alongside FDA-EUA infectious disease tests. The company has achieved significant commercial milestones, including Medicare coverage for RadTox™ and a statewide contract in Florida, supported by a CAP-accredited CLIA lab and global operations.

Therapeutic Areas